Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Explains Potential Failure Of Oral Contraceptives With Obese Women
Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.
generic viagra online
First High-Definition Endoscopic Ultrasound (EUS) Technology Enhances Diagnostic Procedures
Physicians can now provide potentially safer and more accurate diagnostic procedures with the first and only high-definition endoscopic ultrasound (EUS) needle technology. Cook Medical, the only full-line supplier of endoscopic medical devices, has designed a complete line of high-definition EUS biopsy needles that are up to three-times brighter than others on the market. With the addition of the 19 and 25 gage EchoTip® Ultra with High Definition Fine Needle Aspiration (HDFNA™) needles, the EchoTip Ultra HDFNA represents the next level of precision in EUS, an essential diagnostic tool that yields more accurate images of the gastrointestinal (GI) tract than traditional ultrasound and provides minimally invasive access to areas that are traditionally difficult to reach.
News of the day
New Target In Fight Against Osteoporosis, Periodontitis Identified By Dental Researchers
Osteoporosis and periodontitis are common diseases whose sufferers must cope with weakness, injury and reduced function as they lose bone more quickly than it is formed. While the mechanism of bone destruction in these diseases is understood, scientists have had less information about how bone formation is impaired.
Sexual Health

Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia

Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer"s and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers. Dr Ian Massey, Chief Executive Officer and President of Synosia Therapeutics said: "It"s a tribute to our team to be launching this study within months of acquiring SYN-120 through our partnership with Roche. It demonstrates our ability to efficiently and rapidly initiate and conduct clinical trials and to shorten the product development cycle". Alzheimer"s is an incurable disease, predominantly occurring in the elderly. Driven by the ageing population, prevalence of the disease is expected to double by 2025. Industry analysts Lead Discovery state that revenues of approved Alzheimer"s disease drugs across major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $3bn in 2006, with revenues expected to exceed $5bn by 2012. Schizophrenia is a severe form of mental illness, affecting about 24 million people worldwide. Cognitive impairment has long been recognised as a core feature of schizophrenia. It is present in the majority of patients, independent of symptoms such as delusions and hallucinations, and a major cause of poor social and vocational outcome. There are currently no medications approved for the treatment of cognitive impairment in schizophrenia. About SYN-120 SYN-120, a potent and selective antagonist of the 5-HT6 receptor, was discovered by Roche and is now under development by Synosia for the treatment of cognitive impairment. Antagonism of 5-HT6 receptors, which are expressed exclusively in regions of the brain associated with cognition, results in increased concentrations of acetylcholine and glutamate in these regions. Currently, acetylcholinesterase inhibitors are the mainstay for treatment of Alzheimer"s. SYN-120 is anticipated to be more efficacious than the acetylcholinesterase inhibitors and also to be devoid of the side effects (e.g. nausea and vomiting) of this class that result from non-selective increases in acetylcholine in organs other than the brain. Preclinical studies in a variety of models have shown that 5-HT6 antagonists have the potential to help reverse the cognitive losses brought about by Alzheimer"s disease and to improve executive function in schizophrenics. Synosia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009